3,5-Bis(trifluormethyl)cumen | 65638-55-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-Bis(trifluormethyl)cumen
• 英文别名: 3.5-Bis(trifluormethyl)cumen；3,5-Di(tri-fluoromethyl)cumene；1-propan-2-yl-3,5-bis(trifluoromethyl)benzene
• CAS: 65638-55-3
• 化学式: C₁₁H₁₀F₆
• 分子量: 256.191
• InChiKey: JROWVHVMSLMBJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1-(prop-1-en-2-yl)-3,5-bis(trifluoromethyl)benzene 在 氢气 作用下， 生成 3,5-Bis(trifluormethyl)cumen
  参考文献：
  名称：

  Substitution reactions which proceed via radical anion intermediates. 20. Replacement of the nitro group by hydrogen

  摘要：

  DOI：

  10.1021/ja00497a028

文献信息

• Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators
  申请人：Maeda Dean Y.

  公开号：US20100210593A1

  公开（公告）日：2010-08-19

  There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.

  披露了作为药物剂的吡啶和嘧啶羧酰胺化合物，合成过程以及包括吡啶和嘧啶羧酰胺化合物的药物组合物。更具体地，披露了一类CXCR2抑制剂化合物，可用于治疗各种炎症和肿瘤性疾病。
• SUBSTITUTED SULFONYL AMIDES FOR CONTROLLING ANIMAL PESTS
  申请人：Bayer Aktiengesellschaft

  公开号：US20190269134A1

  公开（公告）日：2019-09-05

  The present invention relates to the use of a compound of the general formula (I) in which M and D have the meanings given in the description for controlling animal pests, in particular nematodes.

  本发明涉及使用一种具有一般式(I)的化合物，其中M和D具有描述中给出的含义，用于控制动物害虫，特别是线虫。
• THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION
  申请人：RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

  公开号：US20190031624A1

  公开（公告）日：2019-01-31

  Disclosed herein are compounds of formula I: or a salt thereof and compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods for treating or preventing a bacterial infection in an animal comprising administering to the animal a compound of formula I or a pharmaceutically acceptable salt thereof, alone or in combination with a bacterial efflux pump inhibitor.

  披露于此的是公式I的化合物： 或其盐以及包含公式I化合物或其药用可接受盐的组成。还披露了用于治疗或预防动物细菌感染的方法，包括向动物单独或与细菌外排泵抑制剂联合给药公式I化合物或其药用可接受盐。
• HETEROCYCLIC CETP INHIBITORS
  申请人：Salvati E. Mark

  公开号：US20070161685A1

  公开（公告）日：2007-07-12

  Compounds of formula Ia and Ib wherein A, B, C and R 1 are described herein.

  式Ia和Ib的化合物 其中A、B、C和R1 如本文所述。
• [EN] PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES<br/>[FR] COMPOSÉS [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES À SUBSTITUTION PAR PIPÉRAZINE AYANT DES PROPRIÉTÉS D'ANTAGONISTES DU RÉCEPTEUR A2A
  申请人：MERCK SHARP & DOHME

  公开号：WO2014105664A1

  公开（公告）日：2014-07-03

  Disclosed are compounds of Formula A: (structurally represented) where "RG1", "RG2a", "RG4", "RG5", "MG1", "n" and "m" are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

  公开的是Formula A的化合物：(结构表示)，其中"RG1"，"RG2a"，"RG4"，"RG5"，"MG1"，"n"和"m"在此处被定义为A2A受体的拮抗剂。本文还公开了所述化合物作为A2a受体拮抗剂在潜在治疗或预防A2A受体参与的神经疾病和疾病中的用途。本文还公开了包含这些化合物的药物组合物以及这些药物组合物的用途。